文献速递流行病学与生物统计临床试验与 GCP

2014至2023年东亚与美国注册临床试验趋势演变不同

Registered clinical trial trends evolved differently in East Asia vs the United States during 2014-2023.
PubMed 文献 · J Clin Epidemiol · 2025-04-17

本研究通过国际临床试验注册平台提取中国、日本、韩国、台湾及美国的临床试验数据,分析2014至2023年注册试验趋势及随机对照试验(RCT)特征。结果显示中国临床试验快速增长,2023年以16612项总试验(7798项RCT)超过美国(9100项总试验,4619项RCT),除中国外其他国家近年有所下降。美国更关注心理健康,中国RCT以国内为主,美国国际试验比例更高。

要点

  • 2023年中国注册临床试验16612项(RCT 7798项),美国9100项(RCT 4619项)。
  • 除中国外,日本、韩国、台湾及美国近年注册试验数量有所下降。
  • 中国RCT以国内为主,美国国际试验比例更高,东亚注册库存在信息不一致和缺失。

核心结论

  • 东亚特别是中国在注册临床试验中的重要性日益突出,但以国内为主,现有东亚试验注册库有待改进。

研究设计与样本

  • 通过国际临床试验注册平台提取中国、日本、韩国、台湾和美国的地方注册库及ClinicalTrials.gov数据,分析2014至2023年临床试验趋势,并筛选RCT按地点、目标样本量和疾病类别分类。

主要发现

  • 中国临床试验快速增长,总试验和RCT数量均超过日本和美国。
  • 2023年中国注册总试验16612项(RCT 7798项),美国注册9100项(RCT 4619项)。
  • 除中国外,所有其他国家近年注册试验数量有所下降。
  • 肿瘤疾病和心血管代谢疾病在两地均突出,美国对心理健康的关注增长。
  • 中国RCT以国内为主,美国国际试验比例更高;日本、韩国和台湾呈适度增长,国际试验少于美国。

局限性

  • 现有注册库之间存在一些信息不一致和缺失。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: East Asia, including China, Japan, South Korea, and Taiwan, has become a major hub for clinical trials. However, comprehensive comparisons between ClinicalTrials.gov and local registries remain limited. This study analyzes registered clinical trial trends in East Asia over the past decade (2014-2023) and compares them to trends in the United States (US). STUDY DESIGN AND SETTING: We extracted clinical trial data through the International Clinical Trials Registry Platform, including data from local registries and ClinicalTrials.gov for China, Japan, South Korea, Taiwan, and the US. We analyzed overall clinical trial trends and filtered randomized controlled trials (RCTs), categorizing them by location, target size, and disease category. RESULTS: China experienced rapid growth in clinical trials, surpassing both Japan and the US in total trials and RCTs. By 2023, China led with 16,612 total trials (7798 RCTs), while the US registered 9100 (4619 RCTs). Except for China, all other countries showed some decline in recent years. Neoplastic diseases and cardiovascular and metabolic diseases were prominent in both regions, but the US showed growing focus on mental health. China's RCTs were predominantly domestic, while the United States maintained a higher proportion of international trials. Japan, South Korea, and Taiwan showed moderate growth, with fewer international trials than the US. We recorded some inconsistencies and missing information across existing registries. CONCLUSION: The study highlights the increasing prominence of East Asia, particularly China, in registered clinical trials, though with a primarily domestic focus. Improvements in existing trial registries covering East Asia are desirable.

来源:J Clin Epidemiol,查看原文。版权归原作者所有。

引用

  1. Lee EH, Lee S, Shin JI, et al. Registered clinical trial trends evolved differently in East Asia vs the United States during 2014-2023. J Clin Epidemiol. 2025. PMID: 40250534. doi:10.1016/j.jclinepi.2025.111791

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。